poractant alfa Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5148 129069-19-8

Description:

MoleculeDescription

Synonyms:

  • poractant alfa
  • curosurf
Endogenous pulmonary surfactant (isolated from porcine lungs) reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 18, 1999 FDA CHIESI USA INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
FDA PE N0000008294 Alveolar Surface Tension Reduction
FDA EPC N0000175778 Surfactant
FDA MoA N0000000079 Surfactant Activity
MeSH PA D011663 Pulmonary Surfactants
MeSH PA D019141 Respiratory System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Respiratory distress syndrome in the newborn indication 46775006

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
116075008 SNOMEDCT_US
386999001 SNOMEDCT_US
236381 RXNORM
4021204 VANDF
8499 MMSL
005782 NDDF
d04496 MMSL
D08402 KEGG_DRUG
KE3U2023NP UNII
DB09113 DRUGBANK_ID
CHEMBL1201622 ChEMBL_ID
C068291 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Curosurf HUMAN PRESCRIPTION DRUG LABEL 1 10122-510 SUSPENSION 80 mg ENDOTRACHEAL BLA 15 sections